An official website of the United States government
September 29, 2026 Edition
News
Antiviral drug did not improve Long COVID symptoms
A clinical trial for Long COVID found that treating patients with a common antiviral drug for up to 25 days did not improve symptoms.
News
tRNA treatment may help restore cystic fibrosis proteins
Lipid nanoparticles delivering engineered transfer RNA restored functional proteins in cell and animal models of cystic fibrosis.
News
Bacterial infection may alter developing gut
C. difficile bacteria caused lasting changes to cells in the intestines of newborn mice.
Displaying 561 - 567 of 912
Gut bacteria use nutrient to fight off germs
Research in mice showed that gut bacteria use an essential amino acid to protect the host from invading pathogens.
Study examines measures to slow COVID-19 spread
A modeling study of SARS-CoV-2 spread in Hunan, China could help inform better policies to control the spread of COVID-19 while balancing economic impact.
Lasting immunity found after recovery from COVID-19
The immune systems of more than 95% of people who recovered from COVID-19 had durable memories of the virus up to eight months after infection.
Physician-pharmacist collaboration may improve care for opioid addiction
In a pilot trial, a team approach to treating opioid use disorder that relies heavily on community pharmacists was effective and convenient.
Acute heart transplant rejection detected earlier with new test
Researchers found that a blood test can detect signs of acute heart transplant rejection earlier than more invasive tissue biopsies, the current standard.
Nanoparticles developed for traumatic brain injury
Researchers designed a system to effectively deliver drugs across the blood brain barrier in mice using nanoparticles.
Experimental coronavirus vaccine highly effective
Clinical trial results showed that the vaccine developed by NIH and Moderna is 94.1% effective in preventing symptomatic COVID-19.